137 related articles for article (PubMed ID: 36201369)
1. Oral Dantrolene for Myopathic Symptoms in Malignant Hyperthermia-Susceptible Patients: A 25-Year Retrospective Cohort Study of Adverse Effects and Tolerability.
Ibarra Moreno CA; Kraeva N; Zvaritch E; Jungbluth H; Voermans NC; Riazi S
Anesth Analg; 2023 Mar; 136(3):569-577. PubMed ID: 36201369
[TBL] [Abstract][Full Text] [Related]
2. Malignant hyperthermia testing in probands without adverse anesthetic reaction.
Timmins MA; Rosenberg H; Larach MG; Sterling C; Kraeva N; Riazi S
Anesthesiology; 2015 Sep; 123(3):548-56. PubMed ID: 26068069
[TBL] [Abstract][Full Text] [Related]
3. Oral Dantrolene Reduces Myalgia and Hyperckemia in a Child with RYR1-Related Exertional Myalgia/Rhabdomyolysis.
de Lima Silva EV; Donis KC; Machado FRC; Simão Medeiros L; Aschoff CAM; de Souza CFM; Poswar FO; Saute JAM
J Neuromuscul Dis; 2023; 10(6):1145-1149. PubMed ID: 37781817
[TBL] [Abstract][Full Text] [Related]
4. Malignant hyperthermia in Canada: characteristics of index anesthetics in 129 malignant hyperthermia susceptible probands.
Riazi S; Larach MG; Hu C; Wijeysundera D; Massey C; Kraeva N
Anesth Analg; 2014 Feb; 118(2):381-387. PubMed ID: 23842196
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the segregation of the RYR1 C1840T mutation with segregation of the caffeine/halothane contracture test results for malignant hyperthermia susceptibility in a large Manitoba Mennonite family.
Serfas KD; Bose D; Patel L; Wrogemann K; Phillips MS; MacLennan DH; Greenberg CR
Anesthesiology; 1996 Feb; 84(2):322-9. PubMed ID: 8602662
[TBL] [Abstract][Full Text] [Related]
6. Incidence of malignant hyperthermia reactions in 2,214 patients undergoing muscle biopsy.
Carr AS; Lerman J; Cunliffe M; McLeod ME; Britt BA
Can J Anaesth; 1995 Apr; 42(4):281-6. PubMed ID: 7788824
[TBL] [Abstract][Full Text] [Related]
7. Long term oral Dantrolene Improved Muscular Symptoms in a Malignant Hyperthermia Susceptible Individual.
Butala BN; Kang A; Guron J; Brandom BW
J Neuromuscul Dis; 2016 Mar; 3(1):115-119. PubMed ID: 27854207
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of an episode of malignant hyperthermia using a large dose of dantrolene.
Blank JW; Boggs SD
J Clin Anesth; 1993; 5(1):69-72. PubMed ID: 8442973
[TBL] [Abstract][Full Text] [Related]
9. Muscular body build and male sex are independently associated with malignant hyperthermia susceptibility.
Butala B; Brandom B
Can J Anaesth; 2017 Apr; 64(4):396-401. PubMed ID: 28063098
[TBL] [Abstract][Full Text] [Related]
10. Malignant Hyperthermia Susceptibility and Fitness for Duty.
Lee MA; McGlinch EB; McGlinch MC; Capacchione JF
Mil Med; 2017 Mar; 182(3):e1854-e1857. PubMed ID: 28290972
[TBL] [Abstract][Full Text] [Related]
11. Autosomal dominant canine malignant hyperthermia is caused by a mutation in the gene encoding the skeletal muscle calcium release channel (RYR1).
Roberts MC; Mickelson JR; Patterson EE; Nelson TE; Armstrong PJ; Brunson DB; Hogan K
Anesthesiology; 2001 Sep; 95(3):716-25. PubMed ID: 11575546
[TBL] [Abstract][Full Text] [Related]
12. Malignant hyperthermia (MH) diagnostics: a comparison between the halothane-caffeine- and the ryanodine-contracture-test results in MH susceptible, normal and control muscle.
Hartung E; Koob M; Anetseder M; Schoemig P; Krauspe R; Hogrefe G; Engelhardt W
Acta Anaesthesiol Scand; 1996 Apr; 40(4):437-44. PubMed ID: 8738688
[TBL] [Abstract][Full Text] [Related]
13. Dietary Caffeine Synergizes Adverse Peripheral and Central Responses to Anesthesia in Malignant Hyperthermia Susceptible Mice.
Aleman M; Zhang R; Feng W; Qi L; Lopez JR; Crowe C; Dong Y; Cherednichenko G; Pessah IN
Mol Pharmacol; 2020 Oct; 98(4):351-363. PubMed ID: 32764093
[TBL] [Abstract][Full Text] [Related]
14. Malignant hyperthermia: current perspectives.
Felice-Johnson J; Sudds T; Bennett G
Am J Hosp Pharm; 1981 May; 38(5):646-51. PubMed ID: 7282692
[TBL] [Abstract][Full Text] [Related]
15. Porcine malignant hyperthermia--failure of dantrolene dose response to diagnose susceptibility (halothane effect).
Flewellen EH; Nelson TE; Bee DE
Can Anaesth Soc J; 1980 Jan; 27(1):16-21. PubMed ID: 7353186
[TBL] [Abstract][Full Text] [Related]
16. Abnormal membrane properties of the sarcoplasmic reticulum of pigs susceptible to malignant hyperthermia: modes of action of halothane, caffeine, dantrolene, and two other drugs.
Ohnishi ST; Waring AJ; Fang SR; Horiuchi K; Flick JL; Sadanaga KK; Ohnishi T
Arch Biochem Biophys; 1986 Jun; 247(2):294-301. PubMed ID: 2424370
[TBL] [Abstract][Full Text] [Related]
17. Patients with malignant hyperthermia demonstrate an altered calcium control mechanism in B lymphocytes.
Sei Y; Brandom BW; Bina S; Hosoi E; Gallagher KL; Wyre HW; Pudimat PA; Holman SJ; Venzon DJ; Daly JW; Muldoon S
Anesthesiology; 2002 Nov; 97(5):1052-8. PubMed ID: 12411786
[TBL] [Abstract][Full Text] [Related]
18. Analysis of histomorphology in malignant hyperthermia-susceptible patients.
Orlov D; Keith J; Rosen D; Croul S; Kraeva N; Riazi S
Can J Anaesth; 2013 Oct; 60(10):982-9. PubMed ID: 23888335
[TBL] [Abstract][Full Text] [Related]
19. Malignant hyperthermia susceptibility in patients with exertional rhabdomyolysis: a retrospective cohort study and updated systematic review.
Kraeva N; Sapa A; Dowling JJ; Riazi S
Can J Anaesth; 2017 Jul; 64(7):736-743. PubMed ID: 28326467
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
